NASDAQ •
Healthcare •
Biotechnology •
Quote as of 09/11/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization545.2 mln
Float56.10 mln
Earnings Date11/10/2026
EPS
0.26
Overpriced
P / E
32.50
Overvalued
Piotroski F-Score
5
/ 9
Neutral
Beneish M-Score
4.32
Highly suspicious
1-Year Forecast
13.93
Transformational upside
Relative Strength
18
/ 100
Significantly lagging
Business Description
Arvinas is a New Haven-based biotechnology company focused on developing drugs that eliminate harmful proteins linked to serious diseases. Rather than blocking these proteins, its treatments are designed to remove them from the body entirely using a mechanism the body already employs naturally. The company has several experimental drugs in development targeting conditions such as prostate cancer, breast cancer, certain blood cancers, pancreatic cancer, and Parkinson's disease. Arvinas works alongside major pharmaceutical partners including Pfizer, Roche, and Bayer to advance its research pipeline.
